<DOC>
	<DOCNO>NCT01027884</DOCNO>
	<brief_summary>The aim Phase III study ass efficacy idebenone pulmonary function , motor function , muscle strength quality life patient DMD . Furthermore , safety tolerability idebenone assess .</brief_summary>
	<brief_title>Phase III Study Idebenone Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>This study Phase III , multicenter , randomize , double-blind , placebo-controlled efficacy safety study . DMD patient ( ambulatory non-ambulatory ) age 10-18 year enrol site Europe North America . Study subject randomize 1:1 ratio receive either idebenone ( 900 mg/day ) placebo 3 time day meal 52 week . The primary endpoint difference Catena®/Raxone® placebo change Baseline week 52 Peak Expiratory Flow ( PEF percent predict , PEF % p , measure respiratory muscle strength ) measure hospital-based spirometry . PEF also measure patient home use hand-held ASMA-1 device ( secondary endpoint ) . Other respiratory endpoint include Forced Expiratory Volume 1 second ( percent predict , FEV1 % p , additional measure respiratory muscle strength ) Forced Vital Capacity ( percent predict , FVC % p , measure restrictive lung disease predictive morbidity mortality DMD ) .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Patients 10 18 year age Baseline . 2 . Signed date informed consent . 3 . Documented diagnosis DMD severe dystrophinopathy clinical feature consistent typical DMD diagnosis ( i.e . document delayed motor skill muscle weakness age 5 year ) . DMD confirm mutation analysis dystrophin gene substantially reduce level dystrophin protein ( i.e . absent &lt; 5 % normal ) Western blot immunostain . 4 . Ability provide reliable reproducible repeat PEF within 15 % first assessment ( i.e . Baseline v . Screening ) . 5 . Patients assessed investigator willing able comply requirement study , posse require cognitive ability able swallow study medication . 1 . Patients dependent assist ventilation Screening and/or Baseline ( define noninvasive nocturnal ventilation , daytime noninvasive ventilation continuous invasive ventilation ) . 2 . Patients document DMDrelated hypoventilation assist ventilation need accord current standard care guideline ( e.g . FVC &lt; 30 % ) require opinion Investigator . 3 . Patients percent predict PEF &gt; 80 % Baseline . 4 . Patients unable form mouth seal allow precise respiratory flow measurement mouth pressure . 5 . Symptomatic heart failure ( high probability death within one year Baseline ) and/or symptomatic ventricular arrhythmia . 6 . Participation previous Phase II Phase II Extension study ( SNTII001 SNTII001E ) idebenone . 7 . Participation therapeutic trial and/or intake investigational drug within 90 day prior Baseline . 8 . Use carnitine , creatine , glutamine , oxatomide , herbal medicine within 30 day prior Baseline . 9 . Use coenzyme Q10 vitamin E ( take dose 5 time daily physiological requirement ) within 30 day prior Baseline . 10 . Any previous use idebenone . 11 . Any concomitant medication depressive stimulating effect respiration respiratory tract . 12 . Planned expect spinal fixation surgery study period ( judged investigator ) . 13 . Asthma , bronchitis/COPD , bronchiectasis , emphysema , pneumonia presence nonDMD respiratory illness affect PEF . 14 . Chronic use beta2 agonist use bronchodilating medication ( e.g . inhaled steroid , sympathomimetics , anticholinergic ) . Please note : Chronic use define daily intake 14 day . 15 . Moderate severe hepatic impairment severe renal impairment . 16 . Prior ongoing medical condition laboratory abnormality Investigator 's opinion could adversely affect safety subject . Please note : Patients suffer severe , unstable condition include ( limited ) cancer , autoimmune disease , haematological disease , metabolic disorder immunodeficiency , risk aggravation unrelated study condition , include study accept write Sponsor 's Medical Monitor . 17 . Relevant history current drug alcohol abuse use tobacco/marijuana products/smoking 18 . Known individual hypersensitivity idebenone ingredients/excipients study medication 19 . Systemic glucocorticoid therapy 1 . Chronic use systemic glucocorticoid therapy DMD related condition within 12 month Baseline ( `` 12 month nonuse period '' ) 2 . More 2 round acute systemic glucocorticoid burst therapy ( ≤2 week duration ) nonDMD related condition within 12 month nonuse period 3 . Use round systemic glucocorticoid burst therapy longer 2 week duration within 12 month nonuse period 4 . Use systemic glucocorticoid burst therapy le 8 week prior baseline</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Idebenone</keyword>
	<keyword>Duchenne Muscular Dystrophy ( DMD )</keyword>
	<keyword>Respiratory function</keyword>
	<keyword>Ambulatory non-ambulatory patient</keyword>
	<keyword>Subjects use glucocorticoid</keyword>
</DOC>